Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ресвератрол: капсулы вместо вина
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье представлены сведения о кардиопротективной роли вина, особенно красного. Установлено, что его воздействие обусловлено наличием в вине особой группы полифенолов, главным из которых является ресвератрол. Он увеличивает уровень холестерина липопротеидов высокой плотности и тем самым оказывает антиатерогенный эффект. Кроме того, ресвератрол подавляет оксидативный стресс, асептическое воспаление, улучшает эндотелиальную функцию.
Ключевые слова: алкоголь, вино, кверцетин, ресвератрол, кардиопротективное действие.
Ключевые слова: алкоголь, вино, кверцетин, ресвератрол, кардиопротективное действие.
________________________________________________
The review presents information on the cardioprotective role of vine, red vine in particular.
Its effect has been ascertained to be due to that vine contains a special group of polyphenol, the major flavonoid of which is resveratrol. It increases the level of high-density lipoprotein cholesterol and thus exerts an antiatherogenic effect. Moreover, resveratrol inhibits oxidative stress and aseptic inflammation and improves endothelial function.
Key words: alcohol, vine, quercetin, resveratrol, cardioprotective activity.
Полный текст
Список литературы
1. Kannel WB, Ellison RC. Alcohol and coronary heart disease: the evidence for a protective effect. Clin Chim Acta 1996; 246: 59–76.
2. Rimm EB, Giovannucci EL, Willet WC et al. Protective study of alcohol consumption and risk of coronary disease in men. Lancet 1991; 338: 464–8.
3. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits. Br Med J 1996; 312: 731–6.
4. Gronbaek M, Tjonneland A, Johansen D et al. Type of alcohol and drinking pattern in 56 970 Danish men and women. Eur J Clin Nutr 2000; 54: 174–6.
5. Renaud S, de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992; 339 (8808): 1523–6.
6. Vidavalur R, Otani H et al. Significance of wine and reservation in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006; 11 (3): 217–25.
7. Petrovskiy G, Narasimman G, Dipak KD. Resveratrol in cardiovascular health and disease. Ann NY Acad Scl 1215 (2011) 22–23/NY Academy of Sciences.
8. Lakshman R, Mamatha G, Moakai G et al. Is alcohol beneficial or harmful for cardioprotection? Genes Nutr 2010; 5 (2): 111–20.
9. Walle T, Hsieh F, Delegge M et al. High absorption but very low bioavailability of oral resveratrol in humans. DMD 2004; 32 (12): 1377–82.
10. Krekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996; 24; 312 (7029): 478–81.
11. Robich MP, Pobert M, Osipov MD et al. Resveratrol improves myocardial perfusion in a Swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010; 122: 142–9.
12. Stef G, Csiszar A, Lerea K et al. Resveratrol inhibition of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovascular Pharmacol 2006; 48 (2): 1–5.
13. Fujitaka K, Otani H, Jo F et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011; 31 (11): 842–7.
14. Wong DH, Villanueva JA et al. Resveratrol inhibits the mevalonate pathway and potentiates the antiproliferative effects of simvastatin in rat theca-interstitial. Fertil Steril 2011; 96 (5): 1252-8. EPUB 2011 Sep. 9.
15. Oak M-H, Jasser RL, Bedoui MS et al. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 2004; 110: 1861–7.
16. Ruf JC. Alcohol wine and platelet function. Biol Res 2004; 37: 209–15.
17. Rimm EB, Williams P, Fosher K et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523–8.
18. Pendurthi U, Vijaya L, Rao M. Resveratrol suppresses agonist-induce monocyte adhesion to cultured human endothelial cells. Trombosis Research 2002; 106: 243–8.
19. Pendurthi U, Vijaya L, Rao M. Effect of wine phenolics and stilbene analogues on tissue factor expression in endothelial cells. Trombosis Research 2002; 106: 205–11.
20. Malinowska J, Olas B. Response of blood platelets to resveratrol during a model of hyperhomocysteinemia. Platelets 2011; 22 (4): 277–83.
21. Перова Н.В., Бубнова М.Г., Озерова И.Н. и др. Как влияет ежедневное употребление малых доз алкоголя на систему транспорта холестерина. Рос. кардиол. журн. 2000; 5: 23–8.
22. Сердюк А.П., Метельская В.А., Озерова И.Н. и др. Влияние алкоголя на основные этапы обратного транспорта холестерина. Биохимия. 2000; 65 (11): 1551–7.
23. Boocock DJ, Faust GE, Patel KR et al. Phase l dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16 (6): 1246–52.
24. Mukherjee S, Dudley JL, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010; 8 (4): 478–500.
25. Johnson WD, Morrissey RL, Usborne AL et al. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol 2011; 49 (12): 3319–27.
26. Almeida L, Vaz-da-Silva M, Falcaol A et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising doze study in healthy volunteers. Mol Nutr Food Res 2009; 53: s7–15.
2. Rimm EB, Giovannucci EL, Willet WC et al. Protective study of alcohol consumption and risk of coronary disease in men. Lancet 1991; 338: 464–8.
3. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits. Br Med J 1996; 312: 731–6.
4. Gronbaek M, Tjonneland A, Johansen D et al. Type of alcohol and drinking pattern in 56 970 Danish men and women. Eur J Clin Nutr 2000; 54: 174–6.
5. Renaud S, de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992; 339 (8808): 1523–6.
6. Vidavalur R, Otani H et al. Significance of wine and reservation in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006; 11 (3): 217–25.
7. Petrovskiy G, Narasimman G, Dipak KD. Resveratrol in cardiovascular health and disease. Ann NY Acad Scl 1215 (2011) 22–23/NY Academy of Sciences.
8. Lakshman R, Mamatha G, Moakai G et al. Is alcohol beneficial or harmful for cardioprotection? Genes Nutr 2010; 5 (2): 111–20.
9. Walle T, Hsieh F, Delegge M et al. High absorption but very low bioavailability of oral resveratrol in humans. DMD 2004; 32 (12): 1377–82.
10. Krekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996; 24; 312 (7029): 478–81.
11. Robich MP, Pobert M, Osipov MD et al. Resveratrol improves myocardial perfusion in a Swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010; 122: 142–9.
12. Stef G, Csiszar A, Lerea K et al. Resveratrol inhibition of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovascular Pharmacol 2006; 48 (2): 1–5.
13. Fujitaka K, Otani H, Jo F et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011; 31 (11): 842–7.
14. Wong DH, Villanueva JA et al. Resveratrol inhibits the mevalonate pathway and potentiates the antiproliferative effects of simvastatin in rat theca-interstitial. Fertil Steril 2011; 96 (5): 1252-8. EPUB 2011 Sep. 9.
15. Oak M-H, Jasser RL, Bedoui MS et al. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 2004; 110: 1861–7.
16. Ruf JC. Alcohol wine and platelet function. Biol Res 2004; 37: 209–15.
17. Rimm EB, Williams P, Fosher K et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523–8.
18. Pendurthi U, Vijaya L, Rao M. Resveratrol suppresses agonist-induce monocyte adhesion to cultured human endothelial cells. Trombosis Research 2002; 106: 243–8.
19. Pendurthi U, Vijaya L, Rao M. Effect of wine phenolics and stilbene analogues on tissue factor expression in endothelial cells. Trombosis Research 2002; 106: 205–11.
20. Malinowska J, Olas B. Response of blood platelets to resveratrol during a model of hyperhomocysteinemia. Platelets 2011; 22 (4): 277–83.
21. Перова Н.В., Бубнова М.Г., Озерова И.Н. и др. Как влияет ежедневное употребление малых доз алкоголя на систему транспорта холестерина. Рос. кардиол. журн. 2000; 5: 23–8.
22. Сердюк А.П., Метельская В.А., Озерова И.Н. и др. Влияние алкоголя на основные этапы обратного транспорта холестерина. Биохимия. 2000; 65 (11): 1551–7.
23. Boocock DJ, Faust GE, Patel KR et al. Phase l dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16 (6): 1246–52.
24. Mukherjee S, Dudley JL, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010; 8 (4): 478–500.
25. Johnson WD, Morrissey RL, Usborne AL et al. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol 2011; 49 (12): 3319–27.
26. Almeida L, Vaz-da-Silva M, Falcaol A et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising doze study in healthy volunteers. Mol Nutr Food Res 2009; 53: s7–15.
Авторы
Д.М.Аронов
ФГБУ ГНИЦ профилактической медицины Минздравсоцразвития РФ
aronovdm@mail.ru
ФГБУ ГНИЦ профилактической медицины Минздравсоцразвития РФ
aronovdm@mail.ru
________________________________________________
D.M.Aronov
State Research Center of Preventive Medicine, Ministry of Health and Social Development of the Russian Federation
aronovdm@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.